Teachers Retirement System of The State of Kentucky Has $76.32 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Teachers Retirement System of The State of Kentucky cut its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 6.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,445,300 shares of the company’s stock after selling 166,300 shares during the period. Teva Pharmaceutical Industries makes up about 0.6% of Teachers Retirement System of The State of Kentucky’s investment portfolio, making the stock its 16th largest position. Teachers Retirement System of The State of Kentucky’s holdings in Teva Pharmaceutical Industries were worth $76,317,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Phoenix Financial Ltd. lifted its position in Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after acquiring an additional 3,533,800 shares in the last quarter. National Pension Service increased its holdings in Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after purchasing an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board raised its stake in shares of Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after purchasing an additional 69,000 shares during the period. Oak Harvest Investment Services bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after purchasing an additional 4,306,363 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Barclays boosted their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. The Goldman Sachs Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Finally, Scotiabank boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.78.

Insider Buying and Selling

In other news, insider Eric A. Hughes sold 9,533 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $301,910.11. Following the completion of the sale, the insider owned 107,711 shares of the company’s stock, valued at approximately $3,411,207.37. This represents a 8.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Brian Savage sold 1,127 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the transaction, the insider directly owned 10,914 shares of the company’s stock, valued at $345,646.38. This represents a 9.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 920,901 shares of company stock worth $30,056,789 in the last quarter. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $30.66 on Friday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.52 and a 52-week high of $37.35. The company has a market cap of $35.25 billion, a P/E ratio of 25.55, a P/E/G ratio of 2.73 and a beta of 0.76. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock’s 50-day simple moving average is $31.22 and its 200 day simple moving average is $29.02.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.62 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.